Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

PRIMARY OBJECTIVE:

I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT.

OUTLINE: This is an observational study.

Patients undergo blood sample collection and have their medical records reviewed on study. Patients may also optionally undergo ECG on study.

Inclusion Criteria:

• 18 years of age or older

• Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy

• One of the following:

  • Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
  • Completed chemotherapy with no cardiotoxicity at least two years post treatment
  • Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity

• An understanding of the protocol and its requirements, risks, and discomforts

• The ability and willingness to sign an informed consent

Exclusion Criteria:

- Inability on the part of the patient to understand the informed consent or be compliant with the protocol